Zacks Small Cap Research on MSN4h
ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing…
ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced ...
Sarepta price target lowered to $75 from $80 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Sarepta (SRPT) to $75 from $80 and keeps a Sell rating on the shares. Sarepta’s deal to ...
Sarepta Therapeutics: Strong Buy Rating Amid Strategic Partnership and Promising Growth Potential
Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas ...
Sarepta Therapeutics: Sell Rating Amid Uncertain Pipeline and Financial Risks
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and decreased the price ...
Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
Archer, Scholar Rock, Arrowhead, Iris Energy, Hims & Hers, SoundHound, Joby Aviation, and Urban Outfitters all performed well ...
Trending stocks this week as holiday season begins with Thanksgiving break
Wall Street had a fairly positive, albeit short, trading week with gains in multiple major indexes. The Thanksgiving holiday ...
Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
RIVN, RKLB, SRPT, EXAS, ESTC, ULTA, MRNA, RL, CPRT, SNAP. Any in your portfolio? Citigroup raises price target on ULTA and ...
Business Wire3d
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2024 (the ...
PTC Therapeutics: ALS Drug Fail Kicks Off Critical Year Of Catalysts
PTC Therapeutics faces significant risks with its key revenue sources, Translarna and Emflaza. Find out why I am sticking ...
What is HC Wainwright’s Forecast for SRPT FY2024 Earnings?
Analysts at HC Wainwright issued their FY2024 EPS estimates for Sarepta Therapeutics in a research note issued to investors ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Commerce Bank
Commerce Bank boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 15.7% in the 3rd quarter, ...
Century Therapeutics Stages Highest Single Day Move In 11 Months As Casdin Capital Bumps Its Stake To 5.4%
Shares moves the most in 11-months on a single day basis. Shares of Century Therapeutics Inc IPSC +20.8% Get Free Report ...